353 articles in this topic
New biomarker identifies who's at highest risk for diabetes, hypertension, and liver disease using simple blood test calculations.
New study reveals how the diabetes drug dapagliflozin dramatically alters fat metabolism and kidney function through previously unknown pathways.
New research shows melatonin supplementation during IVF can prevent obesity and glucose problems in offspring by restoring liver function.
Review explores how GLP-1 receptor agonists revolutionize type 2 diabetes care through improved blood sugar control and significant weight reduction.
Phase 3 trial shows once-weekly mazdutide injections led to significant weight loss with minimal side effects in overweight Chinese adults.
Sodium propionate reduced liver inflammation and fat accumulation in diabetic mice fed high-fat, AGE-rich diets through multiple protective mechanisms.
New England Journal review explores the expanding therapeutic potential of GLP-1 drugs beyond diabetes treatment.
New research reveals genetic factors that determine individual responses to weight-loss medications like semaglutide.
Major study of 30,458 patients finds surgery achieves 28% weight loss vs 10% with GLP-1 drugs, while costing significantly less long-term.
New research highlights the critical need for culturally tailored digital health tools to improve diabetes management outcomes.
New GLP-1 drug Foundayo gets fastest FDA approval since 2002, targeting obesity and metabolic health through appetite control.
Multi-omic analysis reveals GLP-1 receptor agonists counter aging processes across multiple organ systems and biological pathways.
